In SUD treatment for pregnant patients, what is a key consideration?

• A. Detox completely before any ongoing treatment.
• B. Medication selection emphasizing maternal-fetal safety; preference for methadone or buprenorphine.
• C. Naltrexone is first-line for all pregnant patients.
• D. No pharmacotherapy allowed.

Answer: (B)

In pregnancy, the priority is to keep both mother and baby safe by stabilizing opioid use and avoiding withdrawal that could stress the fetus or trigger relapse. The best approach is ongoing opioid agonist therapy with either methadone or buprenorphine. These medications provide a controlled, steady opioid effect, prevent withdrawal and cravings, and have a well-established track record for safer perinatal outcomes compared with stopping opioids abruptly. Between the two, buprenorphine often has advantages such as a lower risk of severe neonatal abstinence syndrome and may be easier to initiate, though methadone remains a solid, widely supported option. The key is to manage dosing under prenatal care and coordinate with addiction treatment specialists to support both maternal health and fetal well-being.

Detoxification to completion before ongoing treatment is not advisable because abrupt withdrawal can lead to fetal distress and the likelihood of relapse increases once withdrawal ends. Naltrexone isn’t typically first-line in pregnancy due to limited safety data and the need for detoxification before starting it, which complicates management during pregnancy. No pharmacotherapy is not appropriate when there is active opioid use disorder, as untreated dependence poses greater risks to both mother and baby.